Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective, multicenter, single-arm phase 2 trial indicates no benefit - 11/02/20
Doi : 10.1016/j.jaad.2019.07.035
Henri Montaudié, MD a, b, ⁎ 
, Florence Le Duff, MD a, Catherine Butori, MD c, Véronique Hofman, MD, PhD c, Eric Fontas, MD, PhD d, Coralie Roger-Cruzel, MSc d, Philippe Bahadoran, MD, PhD a, e, Jean-Luc Perrot, MD, PhD f, Eve Desmedt, MD g, Délphine Legoupil, MD h, Thierry Passeron, MD, PhD a, b, Jean-Philippe Lacour, MD a, b
, Florence Le Duff, MD a, Catherine Butori, MD c, Véronique Hofman, MD, PhD c, Eric Fontas, MD, PhD d, Coralie Roger-Cruzel, MSc d, Philippe Bahadoran, MD, PhD a, e, Jean-Luc Perrot, MD, PhD f, Eve Desmedt, MD g, Délphine Legoupil, MD h, Thierry Passeron, MD, PhD a, b, Jean-Philippe Lacour, MD a, b a Department of Dermatology, Archet Hospital, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
b Team 12, Centre Méditerranéen de Médecine Moléculaire, INSERM, U1065, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
c Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
d Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Délégation à la Recherche et à l'Innovation, Nice, France
e Clinical Research Center Archet Hospital, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
f Department of Dermatology, University Hospital of Saint Etienne, Saint Etienne, France
g Department of Dermatology, University Hospital of Lille, INSERM U 1189, Lille, France
h Department of Dermatology, University Hospital of Brest, Brest, France
∗Correspondence to: Henri Montaudié, MD, 151 Route de Saint Antoine de Ginestiere, Hôpital Archet 2, 06200 Nice, France151 Route de Saint Antoine de Ginestiere, Hôpital Archet 2Nice06200France
| Funding sources: This study was supported by a grant from the Société Française de Dermatologie and an Investigator Initiated Trial from LEO Pharma. |
|
| Conflicts of interest: Dr Passeron has received research grants and honoraria from LEO Pharma. Dr Lacour has received research grants from and has been a consultant for LEO Pharma. Dr Montaudié, Dr Duff, Dr Butori, Dr Hofman, Dr Fontas, Ms Roger-Cruzel, Dr Bahadoran, Dr Perrot, Dr Desmedt, and Dr Legoupil have no conflicts of interest to disclose. |
|
| Disclaimer: Société Française de Dermatologie and LEO Pharma had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 82 - N° 3
P. 731-733 - mars 2020 Retour au numéro
Article précédent
- Response from the American Hair Research Society to “Sunscreen and frontal fibrosing alopecia: A review”
- Antonella Tosti, Wilma F. Bergfeld, Angela M. Christiano, Dirk M. Elston, Maria Fernanda Gavazzoni Dias, Lynne Goldberg, Maria K. Hordinsky, John Seykora, Victoria Ceh
- Systemic timolol exposure following topical application to infantile hemangiomas
- Beth A. Drolet, Felix Boakye-Agyeman, Barrie Harper, Kristen Holland, Andrew Lewandowski, Nicole Stefanko, Chiara Melloni, Pediatric Trials Network Steering Committee (See Acknowledgments for a listing of committee members.), Gary Furda, Danny Benjamin, Edmund Capparelli, Gregory L. Kearns, Ian M. Paul, Christoph Hornik, Kelly Wade
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?